CJC 1295-Ipamorelin, Subcutaneous
Uses:
- Fat loss
- Lean muscle mass
- Sleep
- Repair and recovery
Description: CJC-1295
CJC 1295 stimulates growth hormone release via binding to the pituitary. This peptide directly mimics the endogenous Growth Hormone Releasing Hormone (GHRH) typically secreted by the hypothalamus. CJC 1295 comes in 2 chemical forms. One includes a binding group called DAC, or Drug Activity Complex. The DAC bind to serum albumin and significantly increases half-life. However, for many reasons, this is not the preferred product for many patients clinically.
Instead, the tetrasubstituted 29 amino acid modified growth releasing factor often called Mod-GRF is the version of CJC most use clinically. This version of the CJC 1295 outperforms the older and outdated GHRHs such as Sermorelin. The half-life of Sermorelin ranges from 8-12 minutes, whereas the half-life of CJC 1295 extends to 30 minutes.
As a result of better stimulation and release you see many clinical results including fat loss, increases lean muscle mass, better lipid profiles, better deep wave sleep, and increased repair and recovery. Use in combination with Ipamorelin, the CJC is one of the most widely prescribed products.
Description: Ipamorelin
Ipamorelin is a selective GH-Secretagogue and ghrelin, receptor agonist. The potency of ghrelin stimulation can be compared to GHRP6 with less appetite stimulation properties. However, unlike other GH-Secretagogues, this pentapeptide doesn’t release the same volumes of cortisol, acetylcholine, prolactin, and aldosterone. It is for this reason Ipamorelin has been considered the first selective, and best, GH Secretagogue.
Clinical Research
Factor I Secretion by CJC 1295, a Long-Acting Analog of GH-Releasing Hormone, in Healthy Adults
Context: Therapeutic use of GHRH to enhance GH secretion is limited by its short duration of action.
Objective: The objective of this study was to examine the pharmacokinetic profile, pharmacodynamic effects, and safety of CJC 1295, a long-acting GHRH analog.
Design: The study design was two randomized, placebo-controlled, double-blind, ascending dose trials with durations of 28 and 49 d.
Setting: The study was performed at two investigational sites.
Participants: Healthy subjects, ages 21–61 yr, were studied.
Interventions: CJC 1295 or placebo was administered sc in one of four ascending single doses in the first study and in two or three weekly or biweekly doses in the second study.
Main Outcome Measures: The main outcome measures were peak concentrations and area under the curve of GH and IGF-I; standard pharmacokinetic parameters were used for CJC 1295.
Results: After a single injection of CJC 1295, there was a dose-dependent increase in mean plasma GH concentrations by 2- to 10-fold for 6 d or more and in mean plasma IGF-I concentrations by 1.5- to 3-fold for 9-11 d. The estimated half-life of CJC 1295 was 5.8-8.1 d. After multiple CJC 1295 doses, mean IGF-I levels remained above baseline for up to 28 d. No serious adverse reactions were reported.
Conclusions: Subcutaneous administration of CJC 1295 resulted in sustained, dose-dependent increases in GH and IGF-I levels in healthy adults and was safe and relatively well tolerated, particularly at doses of 30 or 60 ug/kg. There was evidence of a cumulative effect after multiple doses. These data support the potential utility of CJC 1295 as a therapeutic agent.
If you want further information about what CJC 1295-Ipamorelin is or about Peptide Therapy, a member of our Functional Medicine team can help you out by providing you with information about it. Just fill out the form below.
Contact Us